Subsidiary of Sichuan Biokin Pharmaceutical (688506.SH) receives milestone payment of $250 million from Roche for the Iza-Bren project.

date
16:56 30/11/2025
avatar
GMT Eight
Baylor Tianheng (688506.SH) announced that its wholly-owned subsidiary SystImmune has recently received a milestone payment of $250 million from BMS. According to the collaboration agreement, the company is also eligible to receive near-term contingent payments of up to $250 million, as well as additional payments of up to $7.1 billion upon reaching specific development, registration, and sales milestones. The milestone payments stipulated in the collaboration agreement are subject to certain conditions and there is uncertainty regarding the final milestone payments.
Sichuan Biokin Pharmaceutical (688506.SH) announced that its wholly-owned subsidiary, SystImmune, has recently received a $250 million milestone payment from BMS. According to the cooperation agreement, the company is also eligible to receive additional milestone payments up to a total of $250 million in the near future, as well as up to $7.1 billion in additional payments upon reaching specific development, registration, and sales milestones. The milestone payments stipulated in the cooperation agreement are subject to certain conditions, and there is still uncertainty regarding the final milestone payments.